Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olezarsen Phase 2 in Hypertriglyceridemia and CVD
NCT03385239Phase 2Completed
- Sponsor
- Akcea Therapeutics
- Start
- Jan 2018
- Primary completion
- Nov 2019
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
A Phase 2 trial of olezarsen in hypertriglyceridemia, sponsored by Akcea Therapeutics. Started Jan 2018; status: completed.
02
Drugs
olezarsen
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT03385239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03385239.